- -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------------- FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): July 10, 2000 -------------------- GENOME THERAPEUTICS CORP. (Exact name of registrant as specified in its charter) MASSACHUSETTS 0-10824 04-2297484 (State or other jurisdiction (Commission File (I.R.S. Employer of incorporation) Number) Identification Number) 100 BEAVER STREET WALTHAM, MASSACHUSETTS 02453 (Address, of principal executive offices, including zip code) (781) 398-2300 (Registrant's Telephone number including area code) -------------------- - -------------------------------------------------------------------------------- Page 1 of 5 pages. Item 5. OTHER EVENTS On July 10, 2000, Genome Therapeutics Corp. issued a press release announcing that the Company raised $44.7 million in additional capital. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1. -2- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENOME THERAPEUTICS CORP. By /s/ Philip V. Holberton ---------------------------------- Name: Philip V. Holberton Title: Chief Financial Officer Date: July 10, 2000 -3- EXHIBIT INDEX 99.1 Press Release dated July 10, 2000 -4-